抗體片段市場規模、佔有率和成長分析（按特異性、片段類型、應用、最終用途和地區分類）－2026-2033年產業預測

預計到 2024 年，全球抗體片段市場規模將達到 76.2 億美元，到 2025 年將達到 80.6 億美元，到 2033 年將達到 126.5 億美元，預測期（2026-2033 年）的複合年成長率為 5.8%。

在對精準、靈活、高效的治療和診斷試劑日益成長的需求推動下，抗體片段市場正崛起為生物製藥行業的關鍵組成部分。 Fab片段、單股可變區片段（scFv）和奈米抗體等先進形式的抗體片段相比傳統單株抗體具有顯著優勢。蛋白質工程、展示技術和計算設計的進步推動了該領域的成長，這些進步提高了片段的穩定性、結合親和性和可生產性。由於需要創新療法來克服完整抗體的局限性，抗體片段正被探索為雙特異性抗體、抗體藥物複合體和CAR-T細胞構建體的基礎組成部分。它們優異的特性不僅使其適用於影像和照護現場診斷，還能滿足個人化醫療的需求。

推動全球抗體片段市場發展的因素

全球抗體片段市場的主要促進因素之一是針對各種疾病（尤其是癌症）的標靶治療需求不斷成長。抗體片段以其對抗原的高特異性和親和性而聞名，與傳統抗體相比，它們在提高療效和最大限度減少副作用方面正變得至關重要。這種向個人化醫療的轉變，加上生物製藥研發的進步以及人們對創新藥物遞送系統日益成長的興趣，正在推動抗體片段的開發和應用。此外，抗體片段體積小，組織穿透性好，清除速度快，使其成為多種治療應用的理想選擇。

全球抗體片段市場限制因素

全球抗體片段市場的主要限制因素之一是研發和生產此類療法的高成本。抗體片段的設計、生產和檢驗流程複雜，需要大量投資，這可能會阻礙小型公司進入市場，並限制創新。此外，嚴格的監管核准以及產品上市所需的漫長週期也是阻礙投資的挑戰。因此，企業在努力推進抗體片段技術的同時，也要克服這些財務和監管方面的障礙，這可能會阻礙市場成長。

全球抗體片段市場趨勢

全球抗體片段市場正經歷顯著成長，這主要得益於其應用領域的不斷拓展，尤其是在腫瘤學和診斷領域。這些片段具有優異的腫瘤穿透性和快速從血液中清除的特性，因此在分子影像和標靶治療的應用日益廣泛。對基於片段的偶聯物和雙特異性抗體的關注，體現了業界對創新治療方案的追求，旨在最大限度地提高治療效果，同時最大限度地減少脫靶效應。這一趨勢凸顯了抗體片段在變革癌症治療模式和提高診斷準確性方面的潛力，鞏固了其作為不斷發展的生物製藥領域關鍵組成部分的地位。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術評估
• 監管環境

全球抗體片段市場規模（按特異性和複合年成長率分類）（2026-2033 年）

• 單株抗體片段
• 多株抗體片段

全球抗體片段市場規模（以片段類型分類）及複合年成長率（2026-2033 年）

• Fab 碎片
• scFv（單鏈可變片段）
• 單域抗體（sdAb）
• 其他

全球抗體片段市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 治療藥物
• 診斷
• 研究工具和工具包

全球抗體片段市場規模（按最終用途和複合年成長率分類）（2026-2033 年）

• 腫瘤學
• 免疫學/自體免疫疾病
• 感染疾病
• 其他

全球抗體片段市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer Inc.
• Novartis AG
• Roche Holding AG
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Amgen Inc.
• Merck KGaA
• Genentech, Inc.
• Ablynx（Sanofi）
• Eli Lilly and Company
• Akeso, Inc.
• Taisho Pharmaceutical Co., Ltd.
• MacroGenics, Inc.
• Harpoon Therapeutics, Inc.
• Chengdu Huasun Technology Group Inc.
• Thermo Fisher Scientific Inc.
• Sartorius AG
• Abcam plc
• Genscript Biotech Corporation

結論與建議

Global Antibody Fragments Market size was valued at USD 7.62 Billion in 2024 and is poised to grow from USD 8.06 Billion in 2025 to USD 12.65 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The antibody fragments market is emerging as a critical component within the biopharmaceutical industry, fueled by a rising demand for precise, adaptable, and efficient therapeutics and diagnostics. Advanced forms of antibody fragments, including Fab fragments, single-chain variable fragments (scFv), and nanobodies, offer distinct advantages over traditional monoclonal antibodies. Growth in this sector is bolstered by advancements in protein engineering, display technologies, and computational design, enhancing fragment stability, binding affinity, and manufacturability. With an increasing need for innovative therapeutic options addressing limitations of full antibodies, antibody fragments are being explored as foundational components for bispecific antibodies, antibody-drug conjugates, and CAR T-cell constructs. Their favorable characteristics make them suitable for imaging and point-of-care diagnostics, while aligning with the needs of personalized medicine approaches.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Fragments market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Fragments Market Segments Analysis

Global Antibody Fragments Market is segmented by Specificity, Fragment Type, Application, End Use and region. Based on Specificity, the market is segmented into Monoclonal Antibody Fragments and Polyclonal Antibody Fragments. Based on Fragment Type, the market is segmented into Fab Fragments, scFv (Single-Chain Variable Fragments), sdAb (Single-Domain Antibodies / Nanobodies) and Others. Based on Application, the market is segmented into Therapeutics, Diagnostics and Research Tools & Kits. Based on End Use, the market is segmented into Oncology, Immunology / Autoimmune Diseases, Infectious Diseases and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Fragments Market

One of the key market drivers for the global antibody fragments market is the increasing demand for targeted therapies in the treatment of various diseases, particularly cancer. Antibody fragments, known for their high specificity and affinity to antigens, are becoming integral in enhancing therapeutic efficacy while minimizing side effects compared to traditional antibodies. This shift towards personalized medicine, coupled with advancements in biopharmaceutical research and the growing focus on innovative drug delivery systems, propels the development and adoption of antibody fragments. Additionally, their smaller size allows for better tissue penetration and faster clearance, making them highly attractive in a range of therapeutic applications.

Restraints in the Global Antibody Fragments Market

One significant market restraint for the global antibody fragments market is the high cost associated with the development and production of these therapeutic agents. The complex processes involved in engineering, manufacturing, and validating antibody fragments can lead to substantial investment requirements, which may restrict market entry for smaller companies and limit innovation. Additionally, stringent regulatory approvals and the lengthy timelines needed to bring these products to market present challenges that could deter investments. As a result, market growth may be hindered as companies navigate these financial and regulatory hurdles while striving to advance their antibody fragment technologies.

Market Trends of the Global Antibody Fragments Market

The Global Antibody Fragments market is experiencing a significant upsurge, particularly driven by their growing application in oncology and diagnostics. These fragments, characterized by their superior tumor penetration and rapid clearance from the bloodstream, are becoming increasingly favored for molecular imaging and targeted therapies. The focus on fragment-based conjugates and bispecific antibodies exemplifies the industry's pursuit of innovative treatment solutions that aim to minimize off-target effects while maximizing therapeutic efficacy. This trend highlights the potential of antibody fragments to revolutionize cancer treatment paradigms and enhance diagnostic accuracy, solidifying their role as critical components in the evolving landscape of biopharmaceuticals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape

Global Antibody Fragments Market Size by Specificity & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibody Fragments
• Polyclonal Antibody Fragments

Global Antibody Fragments Market Size by Fragment Type & CAGR (2026-2033)

• Market Overview
• Fab Fragments
• scFv (Single-Chain Variable Fragments)
• sdAb (Single-Domain Antibodies / Nanobodies)
• Others

Global Antibody Fragments Market Size by Application & CAGR (2026-2033)

• Market Overview
• Therapeutics
• Diagnostics
• Research Tools & Kits

Global Antibody Fragments Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Oncology
• Immunology / Autoimmune Diseases
• Infectious Diseases
• Others

Global Antibody Fragments Market Size & CAGR (2026-2033)

• North America (Specificity, Fragment Type, Application, End Use)
  • US
  • Canada
• Europe (Specificity, Fragment Type, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Specificity, Fragment Type, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Specificity, Fragment Type, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Specificity, Fragment Type, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ablynx (Sanofi)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akeso, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taisho Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harpoon Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chengdu Huasun Technology Group Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abcam plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genscript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations